New immunotherapy combo for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced or metastatic stomach or gastroesophageal junction cancer that has not been treated before with chemotherapy or other systemic therapy (except prior treatments more than 6 months ago).
- Your cancer is HER2-negative (a specific protein marker).
- You are in good enough health (able to do daily activities, with normal blood counts and organ function).
- You have not had previous treatment with immune checkpoint inhibitors or other similar immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy drugs (AK129 and cadonilimab) plus chemotherapy for people with advanced stomach or GEJ cancer who have not had treatment before. The goal is to see if adding these immunotherapies helps shrink tumors or slow cancer growth better than chemotherapy alone.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests three drugs together—tafolecimab, sintilimab, and chemotherapy (SOX)—to treat advanced stomach cancer that cannot be removed by surgery. The drugs work in different ways to help your immune system fight cancer cells.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
This trial tests a new combination of immunotherapy (cadonilimab) and chemotherapy before and after surgery for a specific type of advanced stomach or gastroesophageal junction cancer. It aims to see if adding this immunotherapy helps shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (ipilimumab and sintilimab) plus chemotherapy to shrink gastric cancer that cannot be surgically removed. The goal is to make the cancer small enough for surgery and improve survival.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.